Caseware UK (AP4) 2022.0.179 2022.0.179 true1The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.falseNo description of principal activitytrue2022-03-011 SC469359 2022-03-01 2023-02-28 SC469359 2021-03-01 2022-02-28 SC469359 2023-02-28 SC469359 2022-02-28 SC469359 c:Director2 2022-03-01 2023-02-28 SC469359 d:CurrentFinancialInstruments 2023-02-28 SC469359 d:CurrentFinancialInstruments 2022-02-28 SC469359 d:CurrentFinancialInstruments d:WithinOneYear 2023-02-28 SC469359 d:CurrentFinancialInstruments d:WithinOneYear 2022-02-28 SC469359 d:RetainedEarningsAccumulatedLosses 2023-02-28 SC469359 d:RetainedEarningsAccumulatedLosses 2022-02-28 SC469359 d:RetainedEarningsAccumulatedLosses 2021-03-01 SC469359 c:FRS102 2022-03-01 2023-02-28 SC469359 c:AuditExempt-NoAccountantsReport 2022-03-01 2023-02-28 SC469359 c:FullAccounts 2022-03-01 2023-02-28 SC469359 c:CompanyLimitedByGuarantee 2022-03-01 2023-02-28 iso4217:GBP xbrli:pure

Registered number: SC469359










International Society of Oncology and Biomarkers
(A company limited by guarantee)








Unaudited

Financial statements

Information for filing with the registrar

For the Year Ended 28 February 2023

 
International Society of Oncology and Biomarkers
 
(A company limited by guarantee)
Registered number: SC469359

Balance sheet
As at 28 February 2023


2023

2022
Note

  

Current assets
  

Debtors: amounts falling due within one year
 4 
-
157

Cash at bank and in hand
 5 
608,808
675,068

  
608,808
675,225

Creditors: amounts falling due within one year
 6 
(4,350)
(4,231)

Net current assets
  
 
 
604,458
 
 
670,994

Total assets less current liabilities
  
604,458
670,994

  

  

Net assets excluding pension asset
  
604,458
670,994

Net assets
  
604,458
670,994


Capital and reserves
  

Profit and loss account brought forward
  
670,994
730,707

Loss for the year
  
(66,536)
(59,713)

Profit and loss account carried forward
  
604,458
670,994

  
604,458
670,994


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 13 November 2023.




R J Moro
Director

The notes on pages 2 to 4 form part of these financial statements.

Page 1

 
International Society of Oncology and Biomarkers

(A company limited by guarantee)
 

 
Notes to the financial statements
For the Year Ended 28 February 2023

1.


General information

The company is limited by guarantee and incorporated and domiciled in Scotland. Its registered office is Westby, 64 West High Street, Forfar, DD8 1BJ and its principal place of business is in the UK.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on the going concern basis following the Director's review of the organisations future activites and the strong financial position of the organisation.  

 
2.3

Incoming resources

Income comprises revenue recognised by the company in respect of membership subscriptions, royalty income, congress attendance and investment income.
All membership subscriptions and congress income is recognised in the year to which it relates. Amounts received by the balance sheet date in respect of future years are deferred and income earned during the year but not received by the balance sheet date is accrued.
Royalty income, which is generally earned based upon a percentage of sales or a fixed amount per product sold, is recognised on an accrual basis.

 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 2

 
International Society of Oncology and Biomarkers

(A company limited by guarantee)
 

 
Notes to the financial statements
For the Year Ended 28 February 2023

2.Accounting policies (continued)

 
2.7

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is € Euro.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2022 - 1).


4.


Debtors

2023
2022


Trade debtors
-
157



5.


Cash and cash equivalents

2023
2022

Cash at bank and in hand
608,808
675,068



6.


Creditors: Amounts falling due within one year

2023
2022

Accruals and deferred income
4,350
4,231


Page 3

 
International Society of Oncology and Biomarkers

(A company limited by guarantee)
 

 
Notes to the financial statements
For the Year Ended 28 February 2023


7.


Company status

The company is a private company limited by guarantee and consequently does not have share capital. 
In the event of the dissolution of the organisation, all remaining assets of the organisation will be used exclusively for the scientific purpose of furthering knowledge in oncology, by funding the work and/or interactions of scientists in this field of endeavor. The board will suggest a proposal for the disbursement  of funds and all monetary and non monetary resources, which will be voted upon by the General Assembly.


8.


Controlling party

The company is controlled by its members.


Page 4